Nature6d
FDA approves CSF1R inhibitor for rare, non-cancerous joint tumours
It will compete with Daiichi Sankyo’s CSF1R inhibitor pexidartinib (Turalio), which secured FDA approval in TGCT in 2019. TGCT are rare, non-malignant tumours that form in and near joints.
pharmaphorum4d
Ono poised to join Daiichi in TGCT market after FDA nod
It becomes the second FDA-approved drug for the disease after Daiichi Sankyo's Turalio (pexidartinib), a CSF1R, KIT, and FLT3 inhibitor that was cleared by the FDA in 2019 for TGCT associated with ...
pharmaphorum6d
Merck drug for rare tumour hits phase 3 target
If it makes it to market, the drug will compete with Daiichi Sankyo's Turalio (pexidartinib), a CSF1R, KIT, and FLT3 inhibitor that was cleared for TGCT by the FDA in 2019, and potentially Ono's ...
Seeking Alpha4d
DSKYF Daiichi Sankyo Company, Limited
The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors ...